Last reviewed · How we verify
Intermediate dose nadroparin
Nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.
Nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Thromboprophylaxis in surgical patients, Treatment of deep vein thrombosis, Treatment of pulmonary embolism.
At a glance
| Generic name | Intermediate dose nadroparin |
|---|---|
| Also known as | nadroparin, Fraxiparin |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa, Thrombin (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nadroparin is derived from unfractionated heparin through chemical depolymerization, resulting in a mixture of polysaccharide chains with molecular weights between 4,000 and 6,000 Da. It potentiates antithrombin III-mediated inhibition of activated factor X (factor Xa) more than thrombin, providing anticoagulant activity with a favorable pharmacokinetic profile for subcutaneous administration. The intermediate dose formulation is used for thromboprophylaxis and treatment of thromboembolic disorders.
Approved indications
- Thromboprophylaxis in surgical patients
- Treatment of deep vein thrombosis
- Treatment of pulmonary embolism
- Acute coronary syndrome
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Injection site reactions
- Elevated transaminases
Key clinical trials
- Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk (PHASE4)
- Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy (PHASE4)
- Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation (NA)
- Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy (NA)
- Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism (PHASE3)
- Prophylaxis of Venous Thromboembolism After Bariatric Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |